Clinical trials: Glucagon
Diabetic Kidney Disease
The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease
Diabetic kidney disease (DKD) is a devastating complication of diabetes, that in it's worst form, can lead to early cardiovascular death or kidney failure.
- Trial name
- NCT01847313
- Testing
- Liraglutide
- Where
- Ireland
- Volunteers
- 20 people
- Sponsor
- Karl Neff
Type 1 Diabetes
The Summer Camp Study 2: Blood Glucose Control With a Bi-Hormonal Endocrine Pancreas
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers both insulin and glucagon can improve glycemic control vs.
- Trial name
- NCT02105324
- Testing
- Bionic Pancreas, Usual Care
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Type 1 Diabetes Mellitus
Insulin NovoRapid Versus Actrapid in Treatment of Type 1 Diabetic Patients During Daily Adjustment of Insulin Dose
The main purpose of the study is to investigate the reason for the reduced number of hypoglycaemic attacks in type 1 diabetic patients when, for a period of time, using Insulin Aspart at meals together with NPH insulin mornings…
- Trial name
- NCT00145353
- Testing
- Insulin NovoRapid versus Actrapid
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- Odense University Hospital
Dyslipidemia
Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2
1. To assess whether Glucagon like peptide 2 (GLP-2) affects lipoprotein production (study A) 2. To assess whether GLP-2 affects the release of preformed chylomicrons (study B)
- Trial name
- NCT01958775
- Testing
- GLP-2
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Hypoglycemia
Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia
In this study, participants with Type 1 diabetes received insulin through an infusion into a vein to reduce their blood glucose, and then received nasal glucagon (NG) or glucagon for injection under the skin, and their blood…
- Trial name
- AMG102 (NCT01556594)
- Testing
- Nasal Glucagon 1 mg, Nasal Glucagon 2 mg, SC Glucagon
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Eli Lilly and Company
Kidney Disease, Chronic, Diabetes
Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population.
- Conditions
- Kidney Disease, Chronic, Diabetes, Dialysis, End Stage Kidney Disease (ESRD)
- Trial name
- GUARD-1 (NCT07017270)
- Testing
- Semaglutide Pen
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Unity Health Toronto
Hypertension, Diabetes Type 2
Pharmacogenetics of Ace Inhibitor-Associated Angioedema
The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme…
- Trial name
- NCT01413542
- Testing
- Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Type 2 Diabetes Mellitus
Correlation Between Plasma- and Endothelial DPP-4 Activity
The investigators want to estimate both the endothelial and the plasma activity of dipeptidyl peptidase 4 during different doses of sitagliptin in healthy subjects and patients with type 2 diabetes.
- Trial name
- NCT02192853
- Testing
- sitagliptin
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Short Bowel Syndrome
Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome
The aim of the study is to investigate the effect of the enteric hormone Glucagon-like Peptide (GLP-2) on patients with short bowel syndrome
- Trial name
- NCT00673751
- Testing
- GLP-2
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- Glostrup University Hospital, Copenhagen
Diabetes
Assessment of Intranasal Glucagon on Endogenous Glucose Production
Peripheral glucagon action increases hepatic glucose production. In rodents hypothalamic action of glucagon paradoxically suppresses glucose production.
- Trial name
- NCT02740829
- Testing
- Intranasal glucagon
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Hyperlipidemias
Plasma Lipoprotein Response to Glucagon-like Peptide-2
Some of the fat (triglyceride) from the food humans eat gets stored in the bowel. This triglyceride can then be released into the blood when another meal is consumed or in response to hormones.
- Trial name
- GLP-2 Plasma (NCT03422666)
- Testing
- Teduglutide
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Diabetes
Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon Clearance
The study aims to evaluate the elimination and degradation of glucagon in patients with type 2 diabetes compared to matched healthy subjects.
- Trial name
- MCR Glucagon (NCT02475421)
- Testing
- Glucagon
- Where
- Denmark
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Thirst, Water-Electrolyte Imbalance
Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake
The aim of this study is to elucidate whether GLP-1 analogues influence not only appetite but also thirst perception. It is hypothesized that GLP-1 analogues reduce fluid intake in healthy volunteers compared to Placebo.
- Trial name
- GATE (NCT03141632)
- Testing
- Dulaglutide
- Where
- Switzerland
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
GLP - 1
Exploring the Influence of Glucagon-like Peptide -1 (GLP-1) Medications on Food Cravings, Food Selection, and Food Intake Following Exposure to Food Advertisements
The purpose of this randomized control trial is to compare how food cravings, food selection, and food consumption change in response to frequent food advertisements compared to non-food advertisements in adults taking GLP-1…
- Trial name
- NCT07505134
- Testing
- Food advertisements, Tech advertisements
- Volunteers
- 50 people
- Sponsor
- Penn State University
Healthy Adult Subject
A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects
The main purpose of this study is to evaluate the effect of formulation on relative bioavailability of HDM1002, and the food effect on pharmacokinetics of HDM1002.
- Trial name
- NCT06608329
- Testing
- HDM1002
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Obese Adolescents, Obesity
A Study of XW003 Injection in Chinese Adolescents With Obesity
The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XW003 injection in Chinese adolescents with obesity
- Trial name
- NCT07143227
- Testing
- XW003 injection
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
IPMN, IPMN, Pancreatic
Impact of GLP-1 Receptor Agonists on Patients With IPMN
This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a type of pancreatic cystic neoplasm that can progress to malignancy.
- Conditions
- IPMN, IPMN, Pancreatic, GLP-1, Intraductal Papillary Mucinous Neoplasm of Pancreas
- Trial name
- IPMN-GLP1RA (NCT07014709)
- Testing
- GLP1 receptor agonist
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Hôpital Fribourgeois
Obesity
Evaluation of the Efficacy of the Composite WM Formula in Promoting GLP-1 Secretion
The goal of this clinical trial is to evaluate the physiological effects of a WM Formula on glucagon-like peptide-1 (GLP-1) secretion and glycemic regulation in adults with elevated body fat percentage.
- Trial name
- NCT07097987
- Testing
- WM formula Group, Control group
- Where
- Taiwan
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- TCI Co., Ltd.
Type 2 Diabetes
Treatment With Sitagliptin in Non-obese Japanese Patients With Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) results from early phase insulin secretory defect and insulin resistance. Studies have shown that most of the populations in which insulin resistance is considered to be the primary pathogenetic…
- Trial name
- NCT01642108
- Testing
- Sitagliptin
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Niigata Medical Center
Adolescent Obesity
Antrum Size, Glucagon-like Peptide 1 Levels and Glycemic Control After Sleeve Gastrectomy in Morbid Obese Diabetic Adolescents
Childhood obesity can adversely affect every organ and often has serious consequences. Compare the effect of transection at 2cm vs at 5cm from the pylorus during laparoscopic sleeve gastrectomy on the postoperative weight loss…
- Trial name
- NCT04388059
- Testing
- Laparoscopic sleeve gastrectomy
- Volunteers
- 18 people
- Sponsor
- Tanta University